Pfizer out-licenses global rights to TB drug candidate

18 July 2013

Sequella, a USA-based clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, has licensed pharma behemoth Pfizer’s (NYSE: PFE) exclusive worldwide rights to develop and commercialize sutezolid, a Phase II oxazolidinone antibiotic currently in development for the treatment of tuberculosis (TB).

Under the terms of the deal, Sequella will be solely responsible for completing clinical development and commercializing the product globally. Financial terms of the transaction were not disclosed.

Sutezolid demonstrated potent antibacterial activity against Mycobacterium tuberculosis in the laboratory and in animal models of TB, an aerosol-transmitted infection with a prevalence of over 2 billion people worldwide. It also demonstrated encouraging activity in a Phase IIa Early Bactericidal Activity (EBA) study in TB patients in South Africa.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK